Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced the
appointment of Richard Wenstrup, MD, as Chief Medical Officer.
Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical
leadership experience, including over a decade within the diagnostics industry.
Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical
Officer, for Myriad Genetics, Inc., where he played a key leadership role and
made substantial contributions across the company that helped drive and support
a multi-fold increase in revenue over a decade. In addition to building and
leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively
involved in the company's product development, M&A, and in-licensing activities.
He also previously served as Chief Medical Officer for Myriad Genetic
Laboratories, Inc.
"We are extremely pleased to welcome Rick to the team during this exciting time
at Oxford Immunotec," said CEO, Dr. Peter Wrighton-Smith. "Rick's extensive
leadership experience and the depth and breadth of his clinical, scientific, and
commercial expertise will be immensely valuable as we continue to grow our core
tuberculosis franchise and launch products into the new markets of tick-borne
diseases, blood screening and transplantation."
Prior to joining Myriad Genetics, Dr. Wenstrup served as a tenured Professor of
Pediatrics (Human Genetics) at Cincinnati Children's Hospital Medical Center and
as a tenured Professor of Biomedical Engineering at the University of
Cincinnati. During his time in academia, Dr. Wenstrup was principal investigator
on multiple research grants from the National Institutes of Health (NIH) and the
FDA Orphan Products Grant Program. He also served as a standing member of NIH
review committees and on the scientific advisory boards of several disease-
related foundations. Dr. Wenstrup was the founding director of the Molecular
Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of
Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT®.TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. Also obtained through the acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-
SPOT.PRT test are pipeline products as part of the Company's fourth intended
product line focused on the transplantation market. In addition to these four
product lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.07.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 553575
Anzahl Zeichen: 4888
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
